Compare Medtronic PLC (MDT) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Manulife Financial Corporation — how do they compare? Medtronic PLC trades at $87.75 (market cap $112.24B), while Manulife Financial Corporation trades at $42.32 (market cap $69.48B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Manulife Financial Corporation for 119 Days on average.
| MDT | MFC | |
|---|---|---|
Market Cap | $112.24B | $69.48B |
Volume | 105,663,236 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $105.35 | $44.77 |
52-Week Low | $73.75 | $31.64 |
Typical Hold Time | 63 Days | 119 Days |
Enterprise Value | $131.58B | $64.75B |
Dividend Yield | 3.28% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Manulife Financial (MFC) trades at $41.67, down 2.94% on the day, with a bearish technical signal from moving averages and oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B and a P/E of 16.22. Recent news includes a new $750M subordinated notes offering and executive appointments, while institutional investors like Bank of America added positions in Q2 2026.
The outlook is mixed: analyst consensus is Buy with a $34.24 target, but technicals suggest near-term pressure. Upside drivers include strong insurance sales and Asia growth, while risks involve premium valuation and macroeconomic sensitivity. Cash flow trends show improved operations, but net cash flow declined in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
